Objective, Quantitative, Data-Driven Assessment of Chemical Probes. by Antolin, AA et al.
	   1	  
Objective, Quantitative, Data-Driven Assessment of 
Chemical Probes       
 
Albert A. Antolin,1,2 Joe E. Tym,2 Angeliki Komianou,2 Ian Collins,1 Paul Workman,1* 
and Bissan Al-Lazikani1,2,3,* 
	  
1Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics 
and 2Department of Data Science, The Institute of Cancer Research, 15 Cotswold 
Road, London, SM2 5NG, UK.  
3Lead contact. 
*Correspondence: Paul.Workman@icr.ac.uk (P.W.), Bissan.Al-Lazikani@icr.ac.uk 
(B.A.-L.). 
 
 
SUMMARY 
Chemical probes are essential tools for understanding biological systems and for 
target validation, yet selecting probes for biomedical research is rarely based on 
objective assessment of all potential probes. Here we describe the Probe Miner: 
Chemical Probes Objective Assessment resource – capitalising on the plethora of 
public medicinal chemistry data to empower quantitative, objective, data-driven 
evaluation of chemical probes. We assess >1.8m compounds for their suitability as 
chemical tools against 2,220 human targets and dissect the biases and limitations 
encountered. Probe Miner represents a valuable resource to aid the identification of 
potential chemical probes, particularly when used alongside expert curation. 
 
KEYWORDS 
Chemical probes; chemical tools; large-scale, objective quantitative assessment; 
online public resource. 
	   2	  
INTRODUCTION 
Small-molecule chemical probes are important tools for exploring biological 
mechanisms and play a key role in target validation (Blagg and Workman, 2017; 
Bunnage et al., 2013; Frye, 2010; Workman and Collins, 2010). However, selection 
of chemical probes is largely subjective and prone to historical and commercial 
biases (Arrowsmith et al., 2015; Workman and Collins, 2010). Despite many 
publications discussing the properties of chemical probes and the proposal of ‘fitness 
factors’ to be considered when assessing chemical tools, scientists commonly select 
probes through web-based searchers or previous literature sources that are heavily 
biased towards older and often flawed probes, or use vendor catalogues that do not 
discriminate between probes (Arrowsmith et al., 2015; Blagg and Workman, 2017; 
Workman and Collins, 2010).  
 
The Chemical Probes Portal (Arrowsmith et al., 2015; 
http://www.chemicalprobes.org)  has been launched as a public, non-profit, expert-
driven chemical probe recommendation platform and this emerging resource is 
already contributing to improved chemical probe selection (Blagg and Workman, 
2017). However, expert curation, by definition, can be limited in its coverage and 
would benefit from a complementary, frequently updated, systematic, data-driven, 
objective and comprehensive approach that enables researchers to keep track of the 
fast-moving advances in chemical biology-relevant data at a scale difficult to reach 
with expert curation – allowing unbiased comparison of the quality of large numbers 
of probes. Recently, a scoring system to prioritise chemical tools for phenotypic 
screening based on expert weighting of public and highly-curated private databases 
was described (Wang et al., 2016). However, such resources are not available to the 
majority of translational researchers. A public resource that democratises 
comprehensive data-driven chemical probe assessment is still lacking and would 
greatly contribute to target validation and mechanistic studies performed outside 
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industry. Here, we analyse at scale the scope and quality of published bioactive 
molecules and uncover large biases and limitations of chemical tools and their 
representation in public databases. We provide the online Probe Miner: Chemical 
Probes Objective Assessment resource where we integrate large-scale public data to 
enable objective, quantitative and systematic assessment of chemical probes.  
 
RESULTS 
Probing the Liganded Proteome Using Public Databases 
An ambitious early grand challenge of chemical biology was to identify a chemical 
tool for each human protein (Schreiber, 2005; Workman and Collins, 2010). To 
assess the level of progress towards meeting this challenge, we first defined the set 
of 20,171 curated, validated human proteins in Uniprot (Uniprot Consortium, 2017).  
We then utilised the canSAR knowledgebase integration (Tym et al., 2016; 
http://cansar.icr.ac.uk) of major, curated, public medicinal chemistry data (including 
ChEMBL and BindingDB, see Methods) to determine the fraction of these proteins 
that are known to interact with small molecule compounds (Uniprot Consortium, 
2017; Tym et al., 2016). We find that only 11% (2,220 proteins) of the human 
proteome has been liganded (Figure 1A). This percentage is still very low even if we 
compare it to the 22-40% of the proteome that is estimated to be potentially 
druggable (Figure 1A; Bulusu et al., 2014; Finan et al., 2016; Tym et al., 2016). 
 
To be effective tools for mechanistic biological experiments and target validation, 
chemical probes must satisfy at least some basic criteria for the key properties 
(fitness factors) of potency, selectivity and permeability (Workman and Collins, 
2010). To assess how many of the compounds available in public databases would 
be useful in this context we establish key minimal criteria that should be satisfied: 1) 
Potency: 100 nM or better on-target biochemical activity or binding potency; 2) 
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Selectivity: at least 10-fold selectivity against other tested targets; and 3) 
Permeability: as no large-scale experimental measures of permeability are available, 
we use reported activity in cells (independent of the target and wherever available in 
our sources) as a proxy and set a minimum concentration requirement  of 10 µM 
(see Methods). It is important to stress that these three minimal requirement levels 
do not guarantee that a chemical tool would be suitable for biological investigation 
but all suitable tools should in principle meet these basic requirements. 
 
From the >1.8 million total compounds (TC) available in public databases, we find 
that only 355,305 human active compounds (HAC) have some acceptable level of 
biochemical activity (<10 µM; see Methods) reported against a human protein. Of 
these, 189,736 (10.5% TC, 53% HAC) have measured biochemical activity or binding 
potency of 100nM or better. However, when considering selectivity, we find that only 
93,930 compounds have reported binding or activity measurements against two or 
more targets. Of these, only 48,086 (2.7% TC, 14% HAC) satisfy both our minimal 
potency and selectivity criteria (Figure 1C). Thus, exploration of compound selectivity 
in the medicinal chemistry literature appears alarmingly limited (Figure S1). 
Moreover, we find that the compounds that satisfy our minimal potency and 
selectivity criteria allow the research community to probe only 795 human proteins 
(4% of the human proteome) and at best 18% of the estimated druggable proteome 
(Figures 1A-C). Finally, when additionally considering cellular potency of 10µM or 
better, we find that the number of minimal quality probes is reduced even further to 
2,558 (0.7% HAC). Under these combined criteria, based on the information 
available in public medicinal chemistry databases, compounds fulfilling minimum 
requirements would allow the research community to probe with real confidence only 
250 human proteins (Figure 1B). This represents an unacceptably low percentage 
(1.2%) of the human proteome.  
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The amount of information available for a given protein target will clearly impact any 
statistical analysis of its corresponding chemical tools. To assess the role of differing 
levels of experimental characterisation, we define the ‘Information Richness’ as 
follows: For each target, A, we collect all small molecules (C) shown to be active 
against this target. For each compound we then count the number of targets (T) 
against which it has been tested, regardless of activity level. Thus, the Information 
Richness is IRA= 𝑇!!!!!!  (see Methods for details).  
 
As expected, we find large biases in the amount of data in public medicinal chemistry 
databases available for different protein targets. We also observe a wide range in the 
number of compounds fulfilling our minimum criteria across all the protein targets (0-
204; Figure S2).  For example, some targets have many well-characterised 
compounds, several of which fulfil our minimum criteria; e.g. the metalloprotease 
ADAM17 that has 1,433 active compounds of which 31 satisfy our minimal criteria. 
Other protein targets have large numbers of compounds with differing degrees of 
characterisation, yet few, if any, satisfy our minimal criteria; e.g. JAK1 has 1,560 
active compounds, none of which satisfy our minimal criteria with the data available 
(Figures S2 and S3).  
 
Several factors could influence the observed biases, for example the availability of 
selective probes varies significantly across the analysed protein targets (0-896 
selective compounds). The identification of selective probes may be simpler for some 
targets that have distinctive binding sites (e.g. PPARγ) and difficult for others that 
share closely similar binding sites with numerous family members (e.g. ABL1). 
Increasing the conduct and public availability of large-scale panel screens for many 
compounds against many targets will certainly help expand the information matrix 
required to identify good quality probes. Indeed, half of the 50 protein targets with the 
	   6	  
greatest number of minimum quality probes are kinases, which frequently benefit 
from broad kinome selectivity screens and researchers’ and peer reviewers’ 
awareness that selectivity is a critical issue in this target class (Figure S2). However, 
this brute-force selectivity profiling approach alone is insufficient. Overall, we find 
poor correlation (R2 = 0.1) between the number of reported experimental 
measurements and the number of minimum quality probes (Figure S3). This finding 
indicates that our community needs to be smarter in designing and testing 
compounds – for example, optimising ligand efficiency for probes based on both 
molecular weight and lipophilicity may inherently improve selectivity (Hopkins et al., 
2014) – in addition to increasing the throughput of data generation. 
 
Probing Disease Genes 
Our systematic approach allows us to investigate, more globally, how well existing 
chemical tools equip us to probe mechanistically the function of disease genes – 
which is particularly important for therapeutic target validation. As an exemplar, we 
analyse data for a set of 188 cancer driver genes (CDG) with activating genetic 
alterations (Rubio-Perez et al., 2015) and examine the availability of minimal quality 
chemical probes for these drivers. We find that 73 (39% CDG) have already been 
liganded, and of these 25 (13% CDG) have chemical tools in public databases 
fulfilling minimum requirements of potency, selectivity and permeability (Table S1, 
Figure S4). This is a significantly higher fraction than we find across the proteome as 
a whole (1.2% as described earlier; Figure 1B). The reason for this elevated fraction 
is that the CDGs contain many long established disease genes that have been 
heavily investigated for chemical ligands. Nevertheless 87% of CDG do not have a 
minimum quality chemical tool (Table S1). Moreover, the vast majority of chemical 
tools concentrate on relatively few protein targets, further demonstrating the 
documented trend to focus research efforts in areas of science that are already well-
studied (Table S1, Figure S4; Edwards et al., 2011; Fedorov et al., 2010). This 
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analysis further uncovers a severe lack of chemical probe availability and significant 
bias where tools are available. 
 
Objective Assessment of Chemical Probes 
Given biases and limitations discussed above, it is imperative that researchers can 
comprehensively access all the data publicly available to facilitate objective and data-
driven analysis in order to select the best characterised chemical probes available for 
their protein target of interest – and also so they can also understand probe liabilities 
and limitations at the outset. To this end, we describe a scoring metric that utilises 
>3.9m bioactivity data points publicly available in canSAR (Tym et al., 2016) to 
enable rational prioritization of chemical probes.  
 
To create a metric that allows objective, data-driven ranking of all compounds tested 
for a particular protein target, we developed a set of six scores mirroring our 
previously described fitness factors (Workman and Collins, 2010). Namely, Potency 
Score, Selectivity Score, Cell Score, Structure-Activity Relationship (SAR) Score, 
Inactive Analog Score and PAINS Score (see Methods; Figure S5). For ease of use 
we predefine a default weighting of these scores – which emphasises the importance 
of potency and selectivity (see Methods). However, in addition, we also provide the 
facility for researchers to adapt and customise the weights to suit their own 
questions, expertise and preferences.  
 
Using our default scoring scheme allows us to highlight compounds that make good 
candidates for chemical probes, and defines their key limitations.  For example, we 
assessed 1,346 compounds for the class I PI3 kinase PIK3CB (Figure S6). The five 
highest ranking probes include the clinical candidate pictilisib or GDC-0941 (top rank; 
Folkes et al., 2008) and the frequently used probe PI-103 (2nd ranked; Raynaud et 
al., 2007; Figure 2 and Figure S6), both of which have been widely profiled in large 
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kinome panels. However, our assessment shows that both these compounds have 
certain selectivity liabilities due to cross-PI3K activity (Figure 2; Figure S6). The 
PIK3CB/PIK3CD inhibitor AZD-6482 ranks 10th (Figure 2), due to its partial PI3K 
selectivity towards PIK3CA and PIK3G (Andrs et al., 2015) and most other PIK3CB-
selective chemical series are also represented among the top scoring probes (Andrs 
et al., 2015). It is worth highlighting that Probe Miner can also be useful in 
disincentivising the use of low-quality or flawed chemical probes that continue to 
pollute the chemical biology literature (Arrowsmith et al., 2015). An example is 
LY294002 which is still widely used as a chemical tool inhibitor for PI3 kinase despite 
the fact that its weak potency and lack of selectivity have been widely communicated 
in reviews (Arrowsmith et al., 2015; Blagg and Workman, 2014). LY294002 ranks as 
63rd for PIK3CB in Probe Miner and we hope that its low ranking by objective 
assessment will further discourage the use of this historical but promiscuous 
compound as a probe for PI3 kinases. 
 
Furthermore, our systematic assessment of potential PIK3CB probes additionally 
highlights another set of interesting compounds with properties exemplified by 
canSAR1019166 (Sanchez et al., 2012). This ranks 3rd using our default scoring 
(Figure 2; Figure S6) and is both potent and, unlike pictilisib and PI-103, more 
selective for PIK3CB versus other PI3K proteins. Since no reports of screening 
canSAR1019166 against wider kinase panels are in the public domain as yet, other 
selectivity liabilities may emerge in future. Additionally, this compound may not be 
readily available commercially. There are also potentially important compounds 
whose broader biochemical characterisation is not captured in public medicinal 
chemistry databases, and it is thus not possible to appropriately assess them using 
our unbiased approach. For example, this is the case for the PIK3CB-selective 
clinical candidate GSK-2636771 (Andrs et al., 2015; Mateo et al., 2017) which is 
currently not highly ranked in our resource.  
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Probe Miner: A Public Resource for Objective Assessment of Probes 
To empower the community to utilise the data-driven approach we have created and 
made publicly available Probe Miner: Chemical Probes Objective Assessment 
resource (http://probeminer.icr.ac.uk; Figure 3). This is a user-friendly, interactive 
web-based resource that allows researchers access to the probe data and probe 
rankings for the selected protein target, as well as full customisation of the scoring 
criteria and the ability to deep-dive into the data. We will maintain Probe Miner and 
provide automatic updates following the release of new versions of the public 
databases that are integrated to ensure topicality. 
 
Probe Miner is a target-centric, systematic probe assessment resource. Accordingly, 
Probe Miner is designed to be searched by target. After selection of the desired 
protein target, we provide an interactive graphical overview page (Figure 3 and 
Figure S7-8) – note that Figure 3 shows the large-screen version but the website 
automatically adapts to multiple devices and screen sizes. The overview page 
comprises three major sections as follows: A) Summaries of the data and statistical 
analyses using our algorithm; including coloured icons that provide immediate visual 
indication of the overall quality and known or potential liabilities of compounds for the 
selected target. B) Easy-to-navigate distribution of the twenty highest ranking probes, 
as well as tools to customise the scores, weights and ordering of probes. C) A 
compound viewer interactively linked to the distribution which shows the chemical 
structure and key information for the probe, as well as the values of the six Score 
components as a radar plot. As Probe Miner is intended to complement expert-
curation in The Chemical Probes Portal, we highlight the compounds in our resource 
that are also assessed in the Portal and provide direct links to their individual pages 
at the Portal site. Figure 360 provides a detailed tutorial on how to navigate the 
resource. 
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It is important to stress that the selection of the ‘best’ probes must always be tailored 
to the scientific question under investigation and, therefore, the final decision on 
which tools to select must always be undertaken by the individual researcher. We 
provide our predefined default weightings for calculating the Global Score, which 
users may prefer for speed and convenience. However, for researchers who wish to 
modify ranking criteria and Score components, we provide a ‘Settings’ Panel which 
provides advanced options (Figure 3D and Figure S9; see Methods). Here, 
researchers can set the weights of each of the individual fitness factor Scores that 
contribute to the overall Global Score so that these can be adapted to individual user 
needs. Through the Settings panel (Figure 3D) researchers can also customise the 
display and also the ordering of probes (e.g. according to potency or selectivity) as 
required.  
 
From the Probe Miner overview page for a given protein target, researchers can 
navigate easily to individual probe pages (Figure 3E; Figure S10). These synopsis 
pages provide details of the chemical structure; physicochemical properties; and 
cross-references to key public resources, including canSAR, ChEMBL, BindingDB, 
The Protein Databank, and The Chemical Probes Portal; as well as also indicating 
synonyms for probes and commercial availability (Figure 3E; Figure S9). The raw 
data required to generate the Scores for the given probe are accessible here in a 
tabular format, together with the radar plot displaying the various Scores (from 0-1 
with 1 being the highest rating) in addition to the compound’s Probe Miner rankings. 
The full protein activity profile – the reported activity of the compound against all 
tested proteins as contained in canSAR – is also provided as a bar plot displaying 
the median biochemical activities or binding affinities on a logarithmic scale (e.g. 
pIC50 or pKd) for the compound. This enables a quick and easy overview of the 
selectivity of the compound for the target of interest.  
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To view all chemical probes for a given protein target, a Chemical Probes Table page 
in Probe Miner provides tabular access to all the assessed compounds for that 
target, together with the complete corresponding raw data. This facilitates filtering, 
and allows full download of all the data to enable the chemical biology community to 
further develop assessment and prioritisation methodologies (Figure S11).  
 
The power of our Probe Miner resource is the objective, systematic, regularly 
updated assessment that relies on public medicinal chemistry databases. However, 
as illustrated throughout our analysis, the inevitable limitations in data availability or 
curation can pose a significant challenge in some cases. We believe that arming 
researchers with all the available information and highlighting potential areas of error 
or bias is key to empowering them to make the best-informed decisions. Since 
selectivity is a particular concern with chemical probes (Arrowsmith et al., 2015; 
Blagg and Workman, 2017), in order to alert researchers to cases where this may be 
a problem, we have incorporated a red triangular ‘danger’ icon that warns 
researchers when a chemical probe appears to fail  the criterion of 10-fold selectivity 
against another protein based on the data available to the resource. The easy 
access we provide to the full protein activity profile at the respective chemical probe 
page enables a quick visual impression of the assessed selectivity of each chemical 
tool for the target of interest (Figure S9) while links to expert-curated Chemical 
Probes Portal are provided to draw attention to probes recommended by experts. 
Moreover, our objective assessment performed at scale in Probe Miner can identify 
compounds that we rank as good potential probe candidates, but which are not 
currently curated in The Chemical Probes Portal so that they can be considered for 
evaluation at the Portal. We also highlight potential probes that are not commercially 
available so that vendors can consider them for inclusion in their catalogs.  
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To help address errors and inaccuracies in public databases, we carry out 
continuous curation of the data underlying our Probe Miner resource and have 
established an email address (chemprobes@icr.ac.uk) through which we can be 
contacted by any researcher who identifies such errors or inaccuracies affecting the 
objective assessment of chemical probes. Even high-quality public databases are not 
exempt from errors and inaccuracies that are extremely challenging to identify and 
fix. Data-driven approaches rely on the quality of the data they use and it is thus 
paramount that we as a community address the errors and inaccuracies in public 
databases in order to maximize the benefit derived from them.    
 
Comparing Probe Miner and The Chemical Probes Portal: 
Complementary and Synergistic Resources 
Using our predefined Global Score, we compare the top-ranked chemical probes in 
Probe Miner with the expert-curated probes available in The Chemical Probes Portal 
(Arrowsmith et al., 2015). For this analysis, we focus on the selective probes that are 
curated by The Chemical Probes Portal and that are assigned to no more than two 
targets within the Portal (data collected on 06/02/2017; see Figure S12 and 
Methods). Of the 133 probes in The Chemical Probes Portal on that date, 71 were 
associated with no more than 2 targets and recommended by experts (Rating ≥ 3; 
see Methods). We find that 46 of these 71 probes, corresponding to 45 targets, could 
be mapped to public databases. Using Probe Miner’s present weightings for the 
Global Score, 31 (67%) of the selected 46 Portal probes rank in the top 20 in Probe 
Miner and 18 (39%) rank among the top 5 (Figure S12 and Table S2). Our analysis 
of the 15 expert-recommended probes that fail to reach high rankings uncovers that 
the incompleteness of data available in public databases (often because the probe 
was published in a non-indexed journal) and also the inaccuracy of public data are 
the major limitations (Tables S2 and S3). As the purpose of our resource is to 
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complement The Chemical Probes Portal with strictly objective large-scale, data-
driven information, we explicitly exclude any curated probes that have no data in the 
underlying medicinal chemistry databases. However, as mentioned, we do provide a 
link to The Chemical Probes Portal in the features section of the target overview 
page to alert researchers when a target has probes in the Portal that might not be 
present in public medicinal chemistry databases. Moreover, to address the broader 
lack of coverage of chemical biology data in public medicinal chemistry databases, 
we are actively expanding the canSAR knowledgebase to curate key missing 
literature. In future this growing knowledgebase will further enhance our objective 
assessment and increase the overlap between our resource and The Chemical 
Probes Portal – which is itself also being extended through ongoing inclusion of 
additional probes.  
 
Importantly, our analysis highlights 193 compounds with high rankings (in the top 5) 
in Probe Miner that are not yet curated within The Chemical Probes Portal, and that 
may complement the tools recommended by the Portal to explore the corresponding 
protein targets of interest. This again highlights the clear synergy of combining the 
large-scale objective assessment of all available compounds with in-depth but only 
partially complete coverage of expert curation. To maximize this synergy, we are now 
collaborating with The Chemical Probes Portal to share information and, for example, 
to recommend probes identified by our objective assessment method for expert 
curation at the Portal (see example below). 
 
Use Cases: PARP-1, CHEK2, OPRK1 and ABCC8 
We have selected four use cases to illustrate the value and also current 
limitations of the Probe Miner resource. 
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PARP-1 
The cancer drug target poly(ADP-ribose) polymerase 1 (PARP1) DNA repair enzyme 
has five pan-PARP probes that are recommended by The Chemical Probes Portal. 
Olaparib, veliparib and niraparib are all highly ranked using Probe Miner’s predefined 
Global Score (Figure 3 and 4). However, key information is missing in public 
resources regarding the Portal-listed probes AZ0108 and E7449, the latter published 
in a journal not indexed in public databases (McGonigle et al., 2015). Accordingly, 
these two probes are not highly ranked in Probe Miner (Figure 4). On the other hand, 
our objective assessment resource identifies another probe that scores highly but 
has not yet been curated by The Chemical Probes Portal. This is NMS-P118, a 
recently published PARP1-selective inhibitor that was comprehensively screened for 
kinase selectivity (Papeo et al., 2015) – which is very important given reports of off-
target activity against kinases among PARP inhibitors (Antolín and Mestres, 2014). 
Therefore, NMS-P118 emerges as a potential candidate with which to probe 
specifically for PARP1 (Figure 4).  Based on our findings, we proposed NMS-P118 to 
The Chemical Probes Portal and this chemical probe is now under review for expert 
curation.   
 
CHEK2 
The serine/threonine-protein kinase CHEK2, a cell cycle checkpoint protein, 
exemplifies errors and limitations in the public medicinal chemistry data resources. 
For CHEK2, use of our Global Score initially failed to prioritise the selective chemical 
probe CCT241533 (Caldwell et al., 2011) – which is expert-curated in The Chemical 
Probes Portal – while ranking as the highest-scoring chemical tool the very broadly 
characterised but promiscuous kinase inhibitor sunitinib. We found that CCT241533 
had fallen foul of a series of errors and missing data in public medicinal chemistry 
databases. Most significantly, the affinity of CCT241533 for CHEK2 had been 
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wrongly curated in ChEMBL, making the probe appear non-selective (Figure S13). 
We reported this error to ChEMBL and it has now been corrected in both ChEMBL 
and our canSAR database. As a result, CCT241533 now ranks as the third highest-
scoring probe in Probe Miner (Figure 4).  
 
In considering examples like this, it is important to note that our Selectivity Score 
balances the contribution of actually measured selectivity and also the extent of 
characterisation for potential off-targets. For example, if one probe appears selective 
but has only been tested against two off-targets, while another probe is not 
completely selective but has been tested against hundreds of targets, then our 
Selectivity Score may reward the more widely characterised probe (see Methods for 
details). This is the case in our analysis of sunitinib as a probe. The very thorough 
characterisation of sunitinib against the kinome is the key factor that results in it 
ranking as the top probe when using our predefined weightings for the Global Score 
(see Methods and Figure S14-S18). This further emphasizes the importance of 
carefully evaluating all data available – and, importantly, of expert curation where 
possible – before selecting any chemical probe, regardless of its ranking in Probe 
Miner. 
 
Furthermore, selectivity information is inconsistently reported in public databases 
making the data difficult to automatically extract and compare (e.g selectivity is 
sometimes reported as % inhibition or activity at different concentrations, or even oC 
from Differential Scanning Fluorimetry measurements, rather than bioactivity or 
binding affinity measured in molar concentrations). Our Probe Miner algorithm 
currently uses only selectivity data reported in molar concentrations. Although 
interpretable to a human expert, there is no globally applicable computational method 
to convert % inhibition data to comparable IC50 at scale. Consequently, where 
selectivity data are captured as % inhibition, as for CCT241533 which was tested 
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against a panel of 85 kinases, these data are not incorporated into our current 
Selectivity Score.  
 
OPRK1 
The use of more than one chemical probe with different chemotypes is strongly 
recommended for mechanistic studies and target validation (Blagg and Workman, 
2017). Accordingly, our third use case example, the Kappa opioid receptor OPRK1, 
illustrates how Probe Miner can be used to identify second probes and potentially 
contribute to increase the completeness of The Chemical Probes Portal.  
 
For OPRK1 there is only one chemical probe currently covered in the Portal, namely 
the natural product agonist salvinorin A. While Probe Miner also identifies salvinorin 
A as the highest-ranking probe for OPRK1, it also identifies chemically distinct 
probes for this target such as the drug ICI-199,441 (Weerawarna et al., 1994) which 
is a potent, selective and commercially available agonist and can thus be used in 
conjunction with salvinorin A to probe the biology of the OPRK1 receptor (Figure 4). 
Thus we have recommended the OPRK1 chemical probe ICI-199,441 for 
consideration by The Chemical Probes Portal for expert review that would 
complement our large-scale, data-driven objective assessment in Probe Miner while 
increasing the coverage of OPRK1 inhibitors by the Portal. 
 
ABCC8 
ABCC8 (ATP-binding cassette sub-family C member 8) functions as a modulator of 
ATP-sensitive potassium channels and insulin release and serves as an example of 
how Probe Miner’s broader coverage across the whole liganded proteome can be 
used to aid in the prioritization and selection for expert curation of probes for targets 
that are currently not yet included in The Chemical Probes Portal. Our objective 
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assessment of ABCC8, a subunit of the beta-cell ATP-sensitive potassium channel 
(KATP), identifies the inhibitory, antidiabetic drugs glyburide and repaglinide as the 
highest-ranking probes (Coghlan et al., 2001). These two agents are commercially 
available and could be thus be readily used to probe for this ion channel while 
waiting for more in-depth expert curation of probes for this target at the Portal.  
 
Taken together, these four use cases discussed above represent typical scenarios 
that highlight the synergy and complementarity of the Probe Miner and Chemical 
Probes Portal resources in chemical probe selection.  
 
 
DISCUSSION 
Chemical probes are an essential part of functional genome annotation, mechanistic 
exploration of biology and disease, and validation of drug targets – but there are 
serious issues with their quality, selection and use (Blagg and Workman, 2017). 
Herein, we report: 1) our data-driven, unbiased, objective analysis of large-scale 
public data to catalogue currently available tools and evaluate potential chemical 
probes; 2) our exemplification of the utilization and value of the approach as well as 
the limitations imposed by the current nature of the underlying data; and 3) our 
description of the use of Probe Miner – which we have made freely available to the 
research community as a public resource to facilitate the identification and 
prioritisation of potential chemical probes that should be evaluated further 
(Arrowsmith et al., 2015; www.chemicalprobes.org).  
 
Through our systematic analysis of >3.9 million experimental activities for >1.8 
million compounds in curated public medicinal chemistry databases, we provide 
objective, data-driven systematic scoring of 355,305 compounds against 2,220 
human protein targets. Using our data-driven assessment, we provide quantitative 
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data demonstrating the extent to which the majority of human proteins lack minimal 
quality small-molecule chemical tools that are needed to probe their function. In 
addition, our demonstration of gaps in the description and characterisation of 
chemical tools in public databases highlights especially the extent of our limited 
knowledge of chemical tool selectivity and also uncovers large historical biases in the 
reported exploration of chemical space and the polypharmacology of active 
compounds – resulting in the inequality of available minimal quality probes that we 
identify. It is therefore paramount that the chemical biology community improves the 
quality and especially the degree of broad characterisation of currently available 
chemical tools across multiple targets, and in addition also continues the discovery 
and characterization of tools for as yet non-probed proteins. 
 
Thus while recognizing that the number, quality and proteome-wide coverage of 
chemical probes will increase with time – especially the important factor of degree of 
selectivity profiling – Probe Miner provides additional and distinct resource that will 
be useful both today and in the future to help empower researchers to select the best 
tools available for biomedical research. We believe that our systematic, objective 
assessment resource – derived from the underlying, evolving large-scale medicinal 
chemistry data – is an important addition to the toolbox for chemical probe 
prioritization. Probe Miner can be used by the community to fill the gap while expert-
curation approaches such as The Chemical Probes Portal expand into protein 
families that have not yet been covered, and can also be employed to help prioritize 
probes for subsequent expert curation and assessment at the Portal or by individual 
researchers. However, we show that our unbiased large-scale approach, which 
benefits from regular, automatic updates, will be especially powerful when combined 
with the complementary expert-curated assessments provided by The Chemical 
Probes Portal (Arrowsmith et al., 2015; www.chemicalprobes.org). When used 
together with the experience, knowledge and opinion of the individual investigator, 
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Probe Miner and the Portal provide both the breadth and depth required to make 
informed choices on the selection of chemical probes. In practice, individual 
researchers may in some cases have to make the choice between a well-
characterized but not optimally selective probe versus a less well-characterized but 
seemingly selective one, as illustrated by examples shown, but the combined 
resources help ensure that investigators are fully aware of available knowledge and 
gaps therein. Note also that, in any case, expert guidelines recommend the 
combined use of at least two chemical probes from distinct chemotypes, together 
with at least one inactive control compound (Blagg and Workman, 2014; Workman 
and Collins, 2010). Overall, Probe Miner and The Chemical Probes Portal have 
complementary strengths which will make their continued combined use synergistic 
and mutually beneficial to the user community. 
 
Probe Miner represents, to our knowledge, the first publicly available resource 
enabling objective, data-driven, systematic assessment of chemical tools. We 
demonstrate that our objective data-driven prioritization of chemical tools aligns well	  
with expert recommendation from The Chemical Probes Portal when both 
approaches have access to the same information. However, we also uncover 
incompleteness, inaccuracies and inconsistencies of data deposited in public 
databases that limit the full benefit of our large-scale objective approach. An 
important point to note is that the public databases used in this analysis were 
developed mainly for medicinal chemistry applications and, accordingly, many 
chemical biology publications are not covered. Moreover, we have identified an error 
in public databases that has now been corrected (Figure S13) and also found several 
inaccuracies, particularly regarding the annotation of cell-based EC50 values and 
biochemical IC50 values, as well as inconsistencies regarding the deposition of 
selectivity data in public databases (Table S3).  Therefore, there is a great need to 
better capture and curate medicinal chemistry and chemical biology information from 
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the literature in public knowledgebases if we are to make the most of these 
expensively generated data. Such improvements will also allow further evolution of 
Probe Miner algorithm over time. 
 
We stress that our Probe Miner resource can be used with a predefined weighting of 
fitness factors – in which measures of biochemical activity/binding potency and 
selectivity, as well as surrogate measures of cell permeability, are given greater 
weighting in the overall Global Score.  The preset default weightings for assessing 
and ranking chemical probes may be especially useful for biomedical scientists who 
are not chemical biology or medicinal chemistry experts – which represents a large 
and  important  community that was highlighted recently as requiring advice and 
user-friendly resources when selecting chemical tools for exploring biology and 
conducting target validation (Blagg and Workman, 2017). Alternatively, the weighting 
of different criteria can be customised according to individual researchers’ views and 
needs. For example, expert users may wish to alter the weighting of fitness factors to 
suit their own experience and opinion. Or they may wish to vary the weightings of 
different factors to see how this affects the ranking of probes. 
 
In conclusion, we demonstrate here that objective, quantitative, data-driven large-
scale assessment based on public data can contribute to improving overall 
evaluation and prioritization of chemical probes. We propose that our new Probe 
Miner resource represents a valuable contribution for the identification of potential 
chemical probes, particularly when used alongside expert curation. 
 
 
SIGNIFICANCE 
The selection of appropriate chemical probes is essential for mechanistic biological 
investigation and target validation – but continues to be largely biased and subjective 
	   21	  
and does not benefit from the large-scale data available in public databases. Here, 
we analyse statistically >1.8 million compounds and >2,200 human targets. Our 
objective study provides insights and patterns that can be used objectively in 
assessing and selecting chemical probes. It also uncovers significant biases in the 
exploration of chemical probes in public databases. To enable an objective and 
quantitative assessment of chemical probes, we have developed data-driven probe 
scoring metrics aligned to key properties or fitness factors. To empower the 
community to utilise this knowledge, we have also developed the Probe Miner 
resource (http://probeminer.icr.ac.uk) to enable public access to this information and 
algorithm in a user-friendly framework. We demonstrate how our objective 
assessment generally aligns with expert recommendation from The Chemical Probes 
Portal when the information in public databases is available and accurate, and also 
provides synergistic benefits – for example, through its scale, objectivity and lack of 
bias, and also its quantitative nature. Importantly, we provide examples showing how 
our data-driven assessment can inform selection of probes for expert curation. Thus 
Probe Miner represents a valuable resource to empower the chemical biology and 
general research community towards the selection of high quality chemical probes 
for mechanistic studies and target validation. 
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FIGURE LEGENDS 
Figure 1. Global analysis of chemical probes as described in public databases 
uncovers major limitations and biases. (A) Infographic showing a human silhouette 
representing the human proteome and areas indicating: the proportion of the 
proteome estimated to be druggable but currently unliganded (green; Finan et al., 
2016; Tym et al., 2016); the proportion found to have been already liganded (purple; 
see Methods); and the proportion that can be studied currently with chemical tools 
fulfilling minimum requirements of potency, selectivity and permeability (red; see 
Methods). (B) Venn diagram illustrating the proportion of the 2,220 liganded human 
protein targets that can be studied with chemical tools fulfilling minimum 
requirements of potency, selectivity and permeability. (C) Venn diagram illustrating 
the number of chemical compounds fulfilling minimum requirements of potency, 
selectivity and permeability. 
 
Figure 2. Chemical probe cards for highest-ranked PIK3CB compounds in Probe 
Miner, comprising the chemical structure and the radar plot with the corresponding 
chemical probe scores. Probes also curated by The Chemical Probes Portal include 
their expert ratings in a 4-star format and, when compound is not 10-fold selective 
against another protein, a danger icon (red triangle) is shown to alert the researcher 
that there might be selectivity liabilities when using those compounds as PIK3B 
chemical probes. 
 
Figure 3. Probe Miner resource. Snapshot of the overview and chemical tool pages 
of the resource using the human PARP1 protein as an example. (A) summaries of 
the data and statistical analyses using our algorithm. Coloured icons provide 
immediate visual indication of the overall quality and liabilities of compounds for this 
target and a link to The Chemical Probes Portal is provided when this target has 
expert-curated compounds in the Portal. (B) Easy-to-navigate distribution of the 
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twenty top ranking probes. (C) A compound viewer interactively linked to the 
distribution which shows the chemical structure and key information for the probe, as 
well as the values of the six score components as a radar plot. Compounds also 
expert curated by The Chemical Probes Portal are highlighted in blue and links to the 
Portal are also provided (D) Easy-to-navigate settings panel to enable customisation 
of Global Score, displays and rankings. (E) Individual chemical probe pages where 
detailed information is provided including links to other resources, commercial 
availability, raw data to generate the scores and a target profile to provide an 
overview of compound selectivity (further details in Figures S7-S11).  
 
Figure 4. Analysis of the ranking of chemical probes for the targets PARP1, CHEK2 
and OPRK1. On top, Venn diagram comparing the PARP1 chemical probes 
recommended by The Chemical Probes Portal (see Methods) and the Probe Miner 
resource as ranked by the predefined Global Score. Chemical structures are 
displayed, as well as names, radar plot showing the six Chemical Probe Scores, The 
Chemical Probes Portal reviewers’ rating and Probe Miner ranking when available. 
On the bottom, highest-ranked probes for CHEK2 and OPRK1. 
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STAR METHODS 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources should be directed to and will be fulfilled by the Lead 
Contact, Bissan Al-Lazikani (Bissan.Al-Lazikani@icr.ac.uk). 
 
 
METHOD DETAILS 
 
Definitions	  During	  this	  work	  we	  have	  used	  the	  following	  definitions:	  	  
• Target.	  Human	  protein	  that	  is	  known	  to	  interact	  with	  a	  chemical	  compound.	  	  	  
• Reference	   Target.	   Since	   a	   chemical	   compound	   can	  bind	   to	  multiple	  protein	   targets	   and	  we	   score	   each	  compound-­‐target	   pair,	   the	   reference	   target	   is	   defined	   as	   the	   target	   of	   the	   compound	   that	   is	   being	  evaluated.	  	  
• Potency	  Score.	  Score	  that	  measures	  the	  potency	  of	  the	  biochemical	  interaction	  between	  each	  compound-­‐target	  pair.	  	  
• Selectivity	  Score.	  Score	  that	  measures	  the	  selectivity	  of	  each	  compound-­‐target	  pair.	  Selectivity	  is	  one	  of	  the	   most	   important	   properties	   that	   a	   chemical	   tool	   should	   fulfil	   in	   order	   to	   be	   useful	   to	   study	   the	  biological	   function	   and	   therapeutic	   potential	   of	   a	   specific	   protein	   (Frye,	   2010;	   Workman	   and	   Collins,	  2010).	  However,	   it	   is	   challenging	   to	  measure	  due	   to	   large	  biases	   in	   the	  number	  of	   targets	   screened	   for	  each	  compound	  (Figure	  S14)	  and	  thus	   the	  selectivity	  score	  balances	  our	  actual	  knowledge	  of	  selectivity	  with	  the	  amount	  of	  selectivity	  information	  that	  is	  actually	  available.	  	  	  
• Cell	  Score.	  Since	  no	  large-­‐scale	  experimental	  measure	  of	  permeability	  is	  available,	  we	  use	  cellular	  activity	  as	  a	  proxy.	  Accordingly,	  the	  Cell	  Score	  is	  a	  binary	  score	  that	  measures	  whether	  a	  given	  chemical	  molecule	  is	  known	  to	  be	  active	  in	  cells,	  and	  thus	  accounts	  not	  only	  for	  the	  permeability	  but	  also	  for	  the	  solubility	  and	  cell	  activity	  fitness	  factors	  because	  when	  a	  compound	  is	  active	  in	  a	  cell	  line	  assay	  we	  assume	  it	  fulfils	  minimum	   requirements	   of	   permeability	   and	   solubility	   to	   modulate	   the	   target	   of	   interest	   in	   cells	  (Workman	  and	  Collins,	  2010).	  	  
• SAR	  Score.	  Structure-­‐Activity	  Relationships	  (SAR)	  increase	  confidence	  that	  the	  biological	  effect	  of	  a	  given	  chemical	  tool	  is	  achieved	  via	  the	  modulation	  of	  the	  reference	  target.	  Accordingly,	  the	  SAR	  score	  is	  a	  binary	  score	  measuring	  whether	  there	  are	  (SAR	  Score	  =	  1)	  known	  SAR	  for	  the	  compound-­‐reference	  target	  pair	  (Workman	  and	  Collins,	  2010).	  	  
• Inactive	  Analog	  Score.	  Inactive	  analogs	  can	  be	  useful	  controls	  to	  rule	  out	  off-­‐target	  effects.	  Therefore,	  the	  Inactive	   Analog	   Score	   is	   a	   binary	   score	   measuring	   whether	   there	   are	   known	   inactive	   analogs	   for	   the	  compound-­‐reference	  target	  pair	  (Workman	  and	  Collins,	  2010).	  	  
• PAINS	   Score.	   Pan-­‐assay	   interference	   compounds	   (PAINS)	   are	   those	   that	   interfere	   with	   the	   detection	  methods	   of	   screening	   assays	   and	   are	   thus	   problematic	   artefacts	   that	   have	   been	   identified	   to	   be	  widely	  used	   in	  many	  scientific	  publications	  as	  chemical	   tools,	   thus	   leading	   to	   the	  wrong	  conclusions	  (Baell	  and	  Walters,	   2014).	   There	   are	   several	   computational	  methods	   that	   can	  be	  used	   to	  predict	   PAINS	   and	  other	  potentially	   problematic	   functional	   groups	   in	   biomedical	   and	   cell-­‐based	   chemical	   tools	   (Huggins	   et	   al.,	  2011).	   However,	   none	   of	   the	   available	   computational	  methods	   is	   exempt	   of	   limitations,	   among	   them	   a	  considerable	  number	  of	  false-­‐positives	  (Capuzzi	  et	  al.,	  2017;	  Huggins	  et	  al.,	  2011).	  Accordingly,	  the	  PAINS	  Score	   measures	   whether	   a	   compound	   is	   predicted	   to	   be	   PAINS-­‐free	   using	   the	   substructure	   filters	  proposed	   by	   Baell	   et	   al.	   (see	   Methods)	   as	   a	   pragmatic	   means	   to	   alert	   users	   to	   the	   potential	   risk	   of	  functionality	   in	   the	   molecule	   that	   may	   cause	   misleading	   effects	   in	   biochemical	   or	   cell-­‐based	   assays.	  However,	  to	  reduce	  the	  impact	  of	  false-­‐positives	  we	  give	  this	  PAINS	  Score	  a	  low	  weighting	  in	  the	  default	  Global	  Score	  to	  avoid	  deprioritising	  otherwise	  promising	  molecules.	  Still,	  it	  is	  worth	  highlighting	  that	  the	  PAINS	  Score	  is	  a	  prediction	  calculated	  using	  only	  one	  computational	  method.	  Thus,	  we	  enable	  researchers	  to	   set	   the	  weight	   of	   the	   PAINS	   Score	   in	   the	   Global	   Score	   according	   to	   their	   expert	   judgement	   and	   the	  specific	   assay	   that	   they	   are	   using.	   Moreover,	   researchers	   can	   also	   remove	   the	   PAINS	   Score	   from	   the	  calculation	  of	  the	  Global	  Score	  by	  setting	  the	  weight	  to	  0.	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• Potency	  Score.	  We	  consider	  bioactivity	  data	  on	  compound-­‐target	  pairs	  integrated	  in	  the	  knowledgebase	  canSAR	  (that	  integrates	  high	  quality	  bioactivity	  data	  from	  CHEMBL	  and	  BindingDB)	  (Gaulton	  et	  al.,	  2016;	  Gilson	  et	  al.,	  2016)	  where	  the	  target	   type	   is	  a	  protein,	   the	  protein	   is	  human	  as	  defined	  by	   its	  associated	  Uniprot	   ID	  and	  the	  units	  can	  be	  transformed	  to	   ‘nM’	  (Consortium,	  2017;	  Tym	  et	  al.,	  2016).	  We	  calculate	  the	  median	   of	   all	   the	   reported	   values	   for	   each	   compound-­‐target	   pair	   distinguishing	  between	   ‘=’	   and	   ‘>’	  values	   and	   transform	   them	   into	   pActivity	   values	   (-­‐log(Activity[Molar])).	   We	   consider	   active	   all	  compounds	  with	  a	  median	  pActivity	  below	  10,000	  nM.	  Compounds	  with	  conflicting	  ‘=’	  and	  ‘>’	  data	  for	  the	  same	   target	   are	   considered	   inactive.	  Given	   that	  only	  0.7%	  of	  bioactivities	   are	  below	  100	  picomolar	  but	  they	  strongly	  bias	  the	  normalisation	  of	  the	  potency	  score,	  these	  activity	  values	  (pActivity	  >	  10)	  are	  given	  a	  value	  of	  10.	  	  For	  all	  the	  compound-­‐target	  pairs	  considered	  as	  active,	  the	  potency	  score	  is	  calculated	  as	  the	  normalization	  of	   the	  pActivity	  values	   in	  a	   scale	   from	  0	   (pActivity	  =	  5)	   to	  1	   (pActivity	  ≥	  10).	  There	  have	  been	  arguments	  against	  any	  numerical	  aggregation	  of	  potency	  values	  due	  to	  their	  wide	  variation	  across	  biological	   systems	   and	   technologies,	   but	   the	   proposed	   alternative	   uses	   subjective	   expert	   weighting	   of	  several	  databases	  including	  highly	  curated	  proprietary	  databases	  that	  are	  not	  widely	  accessible	  (Wang	  et	  al.,	  2016).	  We	  have	  thoroughly	   investigated	  cases	  where	  a	  wide	  distribution	  of	  potency	  values	  has	  been	  reported,	  such	  as	  nilotinib	  (CHEMBL255863;	  Wang	  et	  al.,	  2016).	  We	  identify	  that	  these	  wide	  distributions	  are	  often	  due	  to	   inaccuracies	   in	  the	  annotation	  of	  cellular	  EC50	  values	  as	  biochemical	   IC50	  values	  and	  the	  annotation	   of	   data	   from	  mutants	   as	   wild	   type	   proteins	   (Gaulton	   et	   al.,	   2016).	   We	   have	   calculated	   the	  Median	  Absolute	  Deviation	  (MAD)	  of	   the	  potency	  median	  calculated	   for	  each	  compound-­‐target	  pair	  and	  we	  identify	  that	  these	  large	  variations	  affect	  only	  a	  very	  small	  number	  of	  compounds	  (3.6%;	  Figure	  S15).	  We	  provide	   the	  MAD	  to	   facilitate	   the	   identification	  of	   cases	  where	   this	  wide	  distribution	  may	  affect	   the	  reported	  performance	  of	  the	  chemical	  tool.	  These	  results	  support	  the	  use	  of	  high	  quality	  public	  databases	  for	  the	  assessment	  of	  chemical	  tools	  and	  highlight	  the	  need	  to	  better	  curate	  these	  high	  quality	  databases	  to	  make	  the	  most	  of	  this	  expensively	  generated	  data.	  	  
• Selectivity	  Score.	  For	  each	  compound,	  we	  calculate	  a	  different	  selectivity	  score	  for	  each	  of	  the	  proteins	  it	  interacts	  with	   (median	  pActivity	  >	  5)	   considering	   all	   of	   their	   compound-­‐target	   interactions.	   In	  order	   to	  balance	   the	   actual	   knowledge	   of	   selectivity	  with	   the	   amount	   of	   information	   available	   (Figure	   S14),	   the	  Selectivity	  Score	  is	  composed	  by	  three	  different	  factors	  in	  an	  attempt	  to	  reflect	  our	  limited	  cataloguing	  of	  selectivity	  following	  the	  formula	  below:	  	  	   𝑆𝑒𝑙𝑒𝑐𝑡𝑖𝑣𝑖𝑡𝑦  𝑆𝑐𝑜𝑟𝑒 =   𝐹𝑖𝑟𝑠𝑡  𝐹𝑎𝑐𝑡𝑜𝑟 + 𝑆𝑒𝑐𝑜𝑛𝑑  𝐹𝑎𝑐𝑡𝑜𝑟!"#$%&'()  !"#  !"#$%! + 𝑇ℎ𝑖𝑟𝑑  𝐹𝑎𝑐𝑡𝑜𝑟  3 	  	   The	  First	  Factor	  accounts	  for	  the	  actual	  knowledge	  of	  selectivity.	  In	  order	  to	  calculate	  the	  First	  Factor,	  the	  number	  of	  off-­‐targets	  that	  the	  compound	  has	  been	  screened	  against	  is	  calculated	  first,	  without	  including	  the	   target	  being	  evaluated.	   Second,	   the	  median	  pActivity	  values	  are	  used	   to	  discern	  whether	   there	   is	   at	  least	  10-­‐fold	  selectivity	  (1	  log	  unit)	  between	  the	  potency	  of	  the	  compound	  for	  the	  reference	  target	  and	  the	  potency	  for	  each	  off-­‐target	  (pActivityReferenceTarget	  –	  pActivityOff-­‐Target	  ≥	  1).	  The	  10-­‐fold	  selectivity	  cut-­‐off	  has	  been	   previously	   used	   as	   the	   minimum	   selectivity	   requirement	   to	   consider	   that	   a	   chemical	   probe	   is	  selective	  (Oprea	  et	  al.,	  2009).	  If	  there	  is	  10-­‐fold	  selectivity	  between	  the	  potency	  of	  the	  compound	  for	  the	  reference	  target	  and	  the	  potency	  of	  the	  off-­‐target,	  this	  off-­‐target	  is	  considered	  a	  selective	  off-­‐target	  (Figure	  S16).	   Next,	  we	   calculate	   the	   number	   of	   selective	   off-­‐targets.	   The	   First	   Factor	   of	   the	   Selectivity	   Score	   is	  obtained	   by	   dividing	   the	   number	   of	   selective	   off-­‐targets	   by	   the	   total	   number	   of	   off-­‐targets,	   using	   the	  following	  equation:	  	   𝐹𝑖𝑟𝑠𝑡  𝐹𝑎𝑐𝑡𝑜𝑟 =   𝑁𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  10_𝑓𝑜𝑙𝑑  𝑠𝑒𝑙𝑒𝑐𝑡𝑖𝑣𝑒  𝑜𝑓𝑓_𝑡𝑎𝑟𝑔𝑒𝑡𝑠𝑇𝑜𝑡𝑎𝑙  𝑛𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑜𝑓𝑓_𝑡𝑎𝑟𝑔𝑒𝑡𝑠 	  	   Therefore,	  if	  a	  compound-­‐reference	  target	  interaction	  is	  at	  least	  10-­‐fold	  selective	  against	  any	  other	  target,	  the	  value	  of	  the	  first	  factor	  will	  be	  1.	  In	  contrast,	  if	  the	  compound-­‐target	  interaction	  of	  interest	  is	  not	  10-­‐fold	  selective	  against	  any	  other	  compound-­‐target	  interactions,	  the	  first	  factor	  will	  be	  lower	  than	  1	  (Figure	  S16).	  If	  there	  is	  no	  information	  regarding	  any	  off-­‐target,	  the	  Selectivity	  Score	  is	  set	  to	  0.	  	  	  The	  second	  factor	  of	  the	  score	  is	  a	  measure	  of	  the	  amount	  information	  available	  regarding	  selectivity.	  This	  second	   factor	  distinguishes	  between	  compounds	   that	  have	  an	  equal	   first	   factor	  but	  have	  been	  screened	  against	  a	  (very)	  different	  number	  of	  targets.	  Moreover,	  it	  also	  balances	  the	  actual	  knowledge	  of	  selectivity	  –	  measured	  by	  the	  first	  factor	  –	  with	  the	  amount	  of	  information	  available	  regarding	  selectivity	  that	  can	  be	  very	   different	   between	   different	   compounds,	   challenging	   their	   comparison	   (Figures	   S16	   and	   S17).	   In	  order	   to	   calculate	   it,	   we	   have	   developed	   a	   measure	   of	   selectivity	   information	   that	   we	   have	   termed	  Selectivity	   Information	  Richness	   (SIC).	  The	  SIC	   is	  calculated	  as	   the	  summary	  of	   the	  differences	  between	  the	  median	  pActivity	  of	  the	  reference	  target	  and	  the	  pActivity	  of	  each	  off-­‐target	  minus	  one:	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   The	  above	  approach	  enables	  the	  evaluation	  of	  the	  selectivity	  information	  from	  the	  10-­‐fold	  selectivity	  cut-­‐off	   in	   order	   to	   distinguish	   selective	   from	   non-­‐selective	   information	   that	   will	   be	   positive	   and	   negative,	  respectively	  (Figure	  S17).	  Therefore,	  in	  the	  final	  summary	  unselective	  data	  compensate	  for	  selective	  data.	  Interestingly,	  the	  SIC	  could	  also	  be	  regarded	  as	  the	  number	  of	  selectivity	  units	  from	  the	  given	  compound-­‐protein	   interaction.	   To	   calculate	   the	   Second	   Factor	   of	   the	   Selectivity	   Score,	   the	   SIC	   is	   divided	   by	   the	  number	  of	  targets	  that	  would	  be	  modulated	  at	  the	  same	  time	  since	  there	  is	  not	  10-­‐fold	  selectivity	  between	  them,	   therefore	   the	  number	  of	  not	  10-­‐fold	  selective	  off-­‐targets	  plus	   the	   target	  of	   interest,	   following	   this	  formula:	  	   𝑆𝑒𝑐𝑜𝑛𝑑  𝐹𝑎𝑐𝑡𝑜𝑟 =    𝑆𝐼𝐶𝑁𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑛𝑜𝑡  10 − 𝑓𝑜𝑙𝑑  𝑠𝑒𝑙𝑒𝑐𝑡𝑖𝑣𝑒  𝑜𝑓𝑓_𝑡𝑎𝑟𝑔𝑒𝑡𝑠 + 1	  	   This	   division	   enables	   reduction	   the	   SIC	   of	   compound-­‐target	   interactions	   that	   are	   very	   high,	   as	   the	  compound	   has	   been	   screened	   against	   a	   very	   large	   number	   of	   off-­‐targets,	   but	   represent	   suboptimal	  compounds	  to	  probe	  for	  the	  target	  of	  interest	  as	  they	  inhibit	  several	  other	  targets	  with	  similar	  or	  higher	  affinity	  (Figure	  S18).	  	  	  The	  second	  factor	   is	   finally	  normalized	  within	  each	  target	  as	  we	  observe	  that	  different	   targets	  can	  have	  very	  different	  SIC	  ranges.	  The	  main	  reason	  for	  this	  is	  that	  there	  are	  target	  families	  such	  as	  kinases	  where	  family-­‐wide	   profiling	   is	   very	   common	  while	   this	   is	   not	   common	   for	   other	   target	   families	   and	   a	   global	  normalization	  would	  profoundly	  bias	  the	  results.	  	  	  Finally,	   the	   last	   factor	  measures	   the	  percentage	  of	   the	  proteome	   that	   the	   compound	  has	  been	   screened	  against,	  which	  is	  generally	  very	  low,	  with	  the	  following	  formula:	  	  	   𝑇ℎ𝑖𝑟𝑑  𝐹𝑎𝑐𝑡𝑜𝑟 =    𝑁𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑜𝑓𝑓_𝑡𝑎𝑟𝑔𝑒𝑡𝑠 + 1𝑁𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑙𝑖𝑔𝑎𝑛𝑑𝑒𝑑  𝑡𝑎𝑟𝑔𝑒𝑡𝑠	  	   Therefore,	  this	  Third	  Factor	  serves	  as	  a	  reminder	  that	  the	  selectivity	  of	  chemical	  tools	  is	  generally	  a	  major	  unknown.	  Ultimately,	  the	  three	  factors	  are	  added	  and	  the	  final	  score	  is	  normalized	  (Equation	  1).	  Overall,	  the	  Selectivity	  Score	  is	  able	  to	  balance	  different	  aspects	  of	  selectivity;	  however,	  	  how	  compounds	  screened	  against	  a	  very	  different	  number	  of	   targets	  should	  be	  prioritized	  remains	  a	  difficult	  question.	  Our	  aim	   in	  developing	   the	   selectivity	   score	   was	   to	   prioritize	   compounds	   and	   facilitate	   the	   evaluation	   of	   the	  information	   available	   but	   the	   final	   decision	   should	   always	   be	   taken	   by	   the	   researcher	   after	   careful	  evaluation	  of	  available	  information	  and	  tailored	  to	  the	  requirements	  of	  the	  specific	  question.	  	  	  
	  
• Cell	   Score.	  To	  calculate	   the	  Cell	   Score	  we	  compute	   the	  median	  of	   all	   compound	  –	   cell	   line	  bioactivities	  reported	   in	   canSAR	   that	   can	   be	   transformed	   to	   ‘nM’	   (Tym	   et	   al.,	   2016).	  We	   consider	   a	   compound	   has	  positive	   Cell	   Score	   (Score	   =1)	   if	   it	   is	   active	   in	   at	   least	   one	   cell	   line	   considering	   a	   cut-­‐off	   of	   10,000	   nM	  (median	  pActivity	  >	  5).	  This	   cut-­‐off	   is	   set	   to	  minimise	   the	   risk	  of	   considering	  non-­‐specific	  drug	   toxicity	  that	  may	   lead	  to	  cell	  death	  at	  high	  concentrations.	  Compounds	  that	  have	  activity	  values	   less	  potent	  that	  the	  cut-­‐off	  or	  that	  have	  not	  been	  tested	  in	  cell	  line	  assays	  are	  given	  a	  Cell	  Score	  value	  of	  0.	  	  
• SAR	  Score.	  To	  calculate	  the	  SAR	  Score	  we	  first	  calculate	  the	  level	  1	  of	  the	  scaffold	  tree	  for	  all	  compounds	  in	   canSAR	   as	   it	   has	   been	   described	   to	   have	   advantages	   over	   other	   scaffold	   definitions	   (Langdon	   et	   al.,	  2011).	  Next,	  we	  consider	  a	   compound-­‐reference	   target	  pair	  has	  SAR	   (SAR	  Score	  =	  1)	   if	   there	   is	   at	   least	  another	  compound	  reported	  in	  the	  same	  publication	  (identical	  PubMedID)	  with	  the	  same	  level	  1	  scaffold	  active	  against	  the	  reference	  target	  (pActivity	  >	  5).	  	  
• Inactive	  Analog	   Score.	  The	   Inactive	  Analog	  Score	  measures	  whether	   there	  are	  compounds	  sharing	   the	  level	  1	  scaffold	  with	  the	  compound	  being	  evaluated	  that	  are	  reported	  to	  be	  inactive	  (pActivity	  <	  5)	  for	  the	  reference	  target.	  	  	  
• PAINS	   Score.	  We	  apply	  PAINS	   rules	   to	   filter	   compounds	   that	   are	  given	  a	  PAINS	  alert	  by	  giving	   them	  a	  PAINS	  score	  of	  0	  (Baell	  and	  Walters,	  2014).	  	  
• Global	   Chemical	   Probe	   Score.	   The	   Global	   Chemical	   Probe	   Score	   is	   a	   combination	   of	   the	   previous	   6	  Chemical	   Probe	   Scores	   with	   customizable	   weights	   to	   allow	   chemical	   biologists	   to	   prioritize	   the	   best	  chemical	  tools	  for	  the	  specific	  requirements	  of	  their	  experiments.	  We	  have	  predefined	  weights	  for	  a	  case	  where	   selectivity	   is	   twice	   as	   important	   as	   potency,	  which	   in	   turn	   is	   twice	   as	   important	   as	   cell	   activity,	  which	   in	   turn	   is	   twice	  as	   important	  as	  SAR,	   inactive	  analogs	  and	  PAINS	  scores.	  However,	  we	  stress	   that	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different	  proposed	  experimental	  cases	  will	  require	  different	  weights	  of	  these	  scores	  in	  order	  to	  access	  the	  best	   probes.	   We	   do	   not	   think	   that	   there	   is	   a	   unique	   Global	   Score	   applicable	   to	   all	   chemical	   biology	  experiments	  and	  accordingly	   the	  weights	   for	  each	  of	   the	   scores	   can	  be	  personalised	   for	   individual	  user	  needs	  in	  the	  website	  resource.	  Note	  that	  it	  is	  unfortunately	  not	  possible	  to	  fairly	  compare	  our	  Global	  Score	  to	  the	  recently	  developed	  TS	  score	  for	  prioritisation	  of	  chemical	  tools	  for	  phenotypic	  screening	  as	  TS	  uses	  expert	  weighting	   of	   several	   databases,	   including	   highly-­‐curated	   proprietary	   databases	   for	  which	  we	   do	  not	  have	  access	  (Wang	  et	  al.,	  2016).	  The	  Global	  Score	  has	  the	  following	  formula	  (for	  pre-­‐defined	  weights	  a	  =	  8,	  b	  =	  4,	  c	  =	  2,	  d	  =	  e	  =	  f	  =	  1):	  	   𝐺𝑙𝑜𝑏𝑎𝑙  𝑆𝑐𝑜𝑟𝑒 = 𝑎   ∙ 𝑆𝑒𝑙𝑒𝑐𝑡𝑖𝑣𝑖𝑡𝑦!"#$% + 𝑏   ∙ 𝑃𝑜𝑡𝑒𝑛𝑐𝑦!"#$% + 𝑐   ∙   𝐶𝑒𝑙𝑙!"#$% + 𝑑   ∙   𝑆𝐴𝑅!"#$% + 𝑒   ∙   𝐼𝑛𝑎𝑐𝑡𝑖𝑣𝑒𝐴𝑛𝑎𝑙𝑜𝑔𝑠!"#$% +   𝑓   ∙   𝑃𝐴𝐼𝑁𝑆!"#$%𝑎 + 𝑏 + 𝑐 + 𝑑 + 𝑒 + 𝑓 	  	  
• Commercial	  Availability.	  Commercial	  availability	  is	  not	  reported	  as	  a	  score	  because	  we	  believe	  that	  this	  would	  discourage	   the	  supply	  of	   the	  best	   chemical	   tools	  and	  does	  not	   represent	  an	   inherent	  property	  of	  compounds.	  However,	  we	   recognise	   that	   knowing	  whether	   a	   chemical	   tool	   is	   commercially	   available	   is	  important	  for	  chemical	  tool	  selection	  and	  thus	  we	  provide	  this	  information	  in	  each	  chemical	  tool	  synopsis	  page.	  We	   consider	   a	   compound	   is	   commercially	   available	   if	   it	   is	   present	   in	   the	   catalogue	  of	   eMolecules	  (https://www.emolecules.com/)	  that	  comprises	  over	  8	  million	  compounds	   from	  a	  network	  of	  suppliers.	  To	   identify	   if	   a	   compound	   is	   present	   in	   the	   eMolecules	   database	   we	   use	   UniChem	   cross-­‐references	  (Chambers	  et	  al.,	  2013).	  	  	  
	  
Development	  of	  the	  Probe	  Miner:	  Chemical	  Probes	  Objective	  Assessment	  Resource	  We	  have	  developed	  an	  open	  website	  (http://probeminer.icr.ac.uk)	  using	  PHP,	  HTML	  and	  jQuery	  JavaScript	  library	  to	  enable	  public	  access	  to	  the	  Probe	  Miner	  resource	  as	  a	  framework	  for	  chemical	  probe	  prioritization	  using	  data	  integrated	  from	  publicly	  available	  knowledgebases.	  	  	  	  
• Target	  Icons	  	  To	  facilitate	  a	  rapid	  and	  intuitive	  evaluation	  of	  chemical	  probe	  quality	  we	  have	  adapted	  the	  chemical	  probe	  scores	  to	  a	  binary	  representation	  and	  developed	  a	  set	  of	  icons	  that	  can	  be	  shown	  in	  colour	  or	  in	  grey	  scale	  depending	  on	   the	   chemical	   tool	   fulfilling	   certain	   criteria.	  These	   icons	   are	  displayed	   in	   each	   chemical	   tool	  synopsis	  page	  (Figure	  S10).	  Moreover,	  in	  order	  to	  facilitate	  a	  target’s-­‐eye	  view	  of	  chemical	  tool	  quality	  using	  these	   icons,	   the	  number	  of	  probes	   fulfilling	   these	  criteria	   is	  also	  displayed	  below	  the	   icons	   in	  each	  Target	  Overview	  page	  (Figure	  S8a).	  A	  description	  of	  each	  icon	  can	  be	  found	  in	  the	  following	  table:	  	  	  
Icon	  Name	   Description	   Image	  
Target	  Selectivity	  
	  Exemplified	  by	  an	  histogram	  icon,	  it	  shows	  whether	  a	  compound	  inhibiting	  this	  protein	  is	  screened	  against	  at	  least	  one	  other	  target	  and	  has	  at	  least	  10-­‐fold	  selectivity	  against	  any	  other	  target.	  	   	  
Target	  Potency	  
	  	  Exemplified	  by	  a	  test	  tube	  icon,	  it	  shows	  whether	  a	  compound	  inhibits	  this	  target	  with	  at	  least	  100	  nM	  potency.	  	  	   	  
Cell	  Potency	  
	  	  Exemplified	  by	  a	  cell,	   it	  shows	  whether	  a	  compound	  binding	  to	  the	  target	  of	  interest	  is	  active	  in	  a	  cell	  line	  with	  at	  least	  10	  μM	  potency.	  	   	  
Minimum	  Standard	  	  
	  Exemplified	  by	  a	  star,	  it	  is	  an	  aggregate	  of	  the	  three	  previous	  scores	   (that	   themselves	   are	   independent	   from	   each	   other),	  measuring	   whether	   there	   are	   compounds	   inhibiting	   this	  target	  with	  minimum	  standards	  of	  target	  potency	  (	  pActivity	  ≥	   7),	   selectivity	   (at	   least	   one	   tested	   off-­‐target	   and	   10-­‐fold	  selectivity	   against	   any	   off-­‐target)	   and	   cell	   potency	   (activity	  below	  10	  μM	   in	  at	   least	  one	  cell	   line)	   simultaneously.	   It	   is	   a	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key	   icon	   showing	   whether	   a	   compound	   fulfilling	   these	  minimum	  quality	  requirements	  is	  found	  in	  publicly	  available	  databases.	  	  	  
SAR	  	  
	  	  Exemplified	  by	  a	  benzene	  ring,	   it	  measures	  whether	   there	   is	  at	  least	  one	  compound	  binding	  to	  this	  target	  that	  has	  SAR	  as	  defined	  by	  the	  SAR	  Score	  (vide	  supra).	  	   	  
Inactive	  Analog	  
	  Exemplified	  by	  an	  barred	  benzene	  ring,	  it	  measures	  whether	  there	   is	   at	   least	   one	   inactive	   analog	   of	   the	   compound	   as	  defined	  by	  the	  Inactive	  Analog	  Score	  (vide	  supra).	  	  	   	  
PAINS	  
	  Exemplified	   by	   a	   ‘PAINS’	   icon,	   it	   shows	   whether	   there	   is	   a	  compound	   inhibiting	   this	   target	   that	   has	   no	  PAINS	   alerts	   as	  defined	  in	  the	  PAINS	  Score.	  	  	   	  	  	  	  
• Target	   Information	   Richness	   Score.	   In	   order	   to	   inform	   on	   the	   amount	   of	   information	   available,	   we	  develop	   a	   measure	   of	   the	   Information	   Richness	   for	   each	   target,	   not	   only	   in	   terms	   of	   the	   number	   of	  chemical	   compounds	   screened	   against	   it	   but	   also	   their	   characterization	   in	   terms	   of	   selectivity.	  Accordingly,	   for	  each	   target,	   every	  compound	  screened	  against	   it	   is	   counted	  as	  one	  unit	  of	   information.	  Moreover,	   for	  each	  compound	   tested	  against	   that	   target,	   each	  other	   target	   the	  compound	  was	  screened	  against	  is	  also	  counted	  as	  another	  unit	  of	  information.	  Therefore,	  each	  target	  has	  a	  final	  information	  value	  that	  accounts	   for	   the	  number	  of	   screened	  compounds	  plus	   the	  number	  of	  other	   targets	  each	  compound	  was	  screened	  against.	  	  	   𝐼𝑛𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛  𝑅𝑖𝑐ℎ𝑛𝑒𝑠𝑠!"#$%&  ! =    𝑁𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑇𝑎𝑟𝑔𝑒𝑡𝑠  𝑡𝑒𝑠𝑡𝑒𝑑!"#$"%&'  !!!"#$%  !"  !"#$"%&'(!"#$%&  !!!! 	  	  Next,	  each	  target	  is	  ranked	  according	  to	  their	  information	  value.	  The	  Information	  Richness	  score	  reports	  the	  percentile	  of	  each	  target	  in	  terms	  of	  ranking,	  being	  100%	  for	  the	  targets	  with	  the	  highest	  information	  values	  and	  0%	  for	  the	  targets	  with	  the	  lowest	  information	  values.	  	  
Analysis	  of	  the	  ‘Liganded’	  Proteome	  and	  Chemical	  Tools	  for	  Cancer	  genes	  The	   Potency	   Score	   (vide	   supra)	   is	   used	   to	   calculate	   how	  many	   human	   proteins	   interact	  with	   a	   chemical	  molecule	  with	  a	  median	  activity	  below	  10,000	  nM	  (pActivity	  <	  5)	  and	  thus	  represent	  the	  currently	  liganded	  proteome.	  The	  Potency	  Score,	  Cell	  Score,	  the	  number	  of	  off-­‐targets	  and	  the	  number	  of	  selective	  off-­‐targets	  calculated	   for	   the	   Selectivity	   Score	   are	   subsequently	   used	   to	   calculate	   how	   many	   compound-­‐target	  interactions	   fulfilled	   minimum	   chemical	   probe	   requirements.	   Only	   compound-­‐target	   interactions	   with	  median	  pActivity	  ≤	  7,	  reported	  to	  have	  an	  affinity	  below	  10,000	  nM	  in	  at	  least	  one	  cell	  line,	  screened	  against	  at	  least	  one	  other	  target	  and	  at	  least	  10-­‐fold	  selective	  against	  all	  other	  targets	  screened	  are	  selected.	  Finally,	  the	   absolute	  number	  of	  human	  protein	   targets	   and	   chemical	  molecules	   selected	   is	   calculated.	   In	  order	   to	  compare	   Information	   Richness	   with	   chemical	   tool	   quality,	   information	   values	   calculated	   for	   the	   Target	  Information	   Richness	   Score	   (vide	   supra)	   are	   compared	   to	   the	   number	   of	   compounds	   fulfilling	  minimum	  chemical	   probe	   requirements	   for	   each	   target	   (Figure	   S3).	   For	   the	   analysis	   of	   minimum-­‐quality	   chemical	  tools	   for	   cancer	   driver	   genes	  we	   extracted	   the	   chemical	   tools	   fulfilling	  minimum	   requirements	   from	   the	  previous	  analysis	  and	  annotated	  to	  the	  188	  cancer	  targets	  identified	  as	  potentially	  driving	  cancer	  in	  a	  recent	  pan-­‐cancer	  analysis	  (Rubio-­‐Perez	  et	  al.,	  2015).	  	  	  	  
Analysis	  of	  Chemical	  Probes	  from	  The	  Chemical	  Probes	  Portal	  All	  the	  chemical	  probes	  from	  The	  Chemical	  Probes	  Portal	  are	  downloaded	  from	  The	  Chemical	  Probes	  Portal	  website	   (http://www.chemicalprobes.org/browse_probes;	   downloaded	   06/02/2017)	   including	   key	  information	   such	   as	   name,	   target(s)	   names,	   PubChem	   CID	   and	   Average	   Recommendation	   (Table	   S2)	  (Arrowsmith	  et	  al.,	  2015).	  Probes	  are	  mapped	  to	  canSAR	  compound	  IDs	  when	  possible	  using	  the	  provided	  PubChem	  CIDs,	  ChEMBLIDs	  or	  SMILES.	  The	  most	  potent	  target	  from	  the	  reported	  values	   is	  considered	  for	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the	   analysis	   and	   mapped	   to	   UniprotIDs	   via	   the	   provided	   gene	   names	   (Table	   S2).	   The	   oldest	   Primary	  Reference	   of	   the	   probe	   is	   also	   recorded	   and	  mapped	   to	   PubMed	   ID,	   journal	   name	   and	   publication	   year	  (Table	  S2).	  Since	  our	  assessment	  is	  performed	  at	  the	  single	  target	  level,	  we	  focus	  on	  the	  selective	  probes	  for	  the	   comparative	   analysis.	   From	   the	  133	  probes	  available	   in	   the	   resource	  at	   the	  accession	  date,	  109	  were	  associated	  with	  no	  more	  than	  two	  targets	  (Table	  S2).	  Next,	  we	  selected	  probes	  that	  have	  a	  SAB	  Rating	  ≥	  3	  and	   are	   thus	   recommended	   by	   experts	   following	   The	   Chemical	   Probes	   Portal	   guidelines	  (http://www.chemicalprobes.org/sab-­‐rating-­‐system).	  From	  the	  109	  selective	  probes,	  71	  are	  recommended	  by	   experts.	   From	   the	   71	   recommended	   probes,	   46	   could	   be	   mapped	   to	   publicly	   available	   medicinal	  chemistry	  databases	  and	  have	  affinity	  data	  for	  the	  primary	  target	  that	  enables	  the	  calculation	  of	  the	  scores.	  It	  is	  worth	  noting	  that	  many	  of	  the	  probes	  that	  could	  not	  be	  mapped	  were	  published	  in	  2016	  or	  2017	  and	  they	  had	  not	  yet	  been	  included	  in	  public	  databases	  such	  as	  ChEMBL.	  From	  these	  46	  probes,	  their	  ranking	  for	  their	  intended	  target	  is	  calculated	  according	  to	  our	  predefined	  Global	  Score	  (Table	  S2).	  In	  30	  cases	  (65%),	  the	   recommended	   probes	   are	   ranked	   among	   the	   top	   20	   by	   the	   predefined	   Global	   Score	   and	   in	   17	   cases	  (37%)	  the	  recommended	  probes	  rank	  among	  the	  top	  5.	  Analysis	  of	  the	  15	  probes	  that	  are	  recommended	  by	  The	  Chemical	  Probes	  Portal	  but	  do	  not	  rank	  among	  the	  top	  20	  by	  the	  Global	  Score	  uncovers	  that	  the	  main	  reasons	  for	  not	  ranking	  correctly	  are	  data	  incompleteness	  (mainly	  because	  key	  information	  was	  published	  in	  a	  non-­‐indexed	  publication)	  or	  data	  inaccuracy	  (mainly	  EC50s	  curated	  as	  IC50s;	  Tables	  S2	  and	  S3).	  	  	  
DATA AND SOFTWARE AVAILABILITY 
 
All the data to calculate all the scores can be consulted and downloaded from Probe Miner’s website, 
either from each probe-target page or by accessing the ‘Display All’ section on each target overview 
page, from which a download button can be used to download all the raw data. E.g: 
 
http://probeminer.icr.ac.uk/#/P09874/compounds 
 
 
KEY RESOURCES TABLE 
 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Deposited Data 
ChEMBL22 ChEMBL Gaulton et al., 2016 
BindingDB BindingDB Gilson et al., 2016 
canSAR v3 canSAR Tym, et al., 2016 
Software and Algorithms 
Level 1 of the scaffold tree Scaffold Tree Langdon et al., 2011 
PAINS FILTERS PAINS Baell and Walters, 2014 
 
 
